Pharmacological Evaluation of a New Ca++ Antagonist, 8-(N, N-Diethylamino)Octyl 3,4,5-Trimethoxybenzoate Hydrochloride (TMB-8): Studies in Skeletal Muscles

Authors:
  • MMMarjorie H. Malagod&Iacute
    Marjorie H. Malagod&Iacute
  • CCC.Y. Chiou
    C.Y. Chiou

Abstract
The pharmacology of 8-(N, N-diethyl-amino)octyl 3,4,5-trimethoxybenzoate (TMB-8) has been studied in several skeletal muscle preparations. TMB-8 inhibited responses of skeletal muscle produced by electrical stimulation of motor nerves with ID50s of 1.6 × 10–sM to 4.2 × 10–5M. TMB-8 also inhibited responses of skeletal muscle produced by direct electrical stimulation with an ID50 of 11 × 10–5M. TMB-8 insurmountably inhibited skeletal muscle responses to a receptor specific agent (acetylcholine) as well as to an agent whose action is not mediated via specific membrane receptors (KCl) with ID50s of 1.8 X 10–5M to 3.4 X 10–5M. Responses to caffeine, an agent that releases Ca++ from the sarcoplasmic reticulum, were competitively antagonized by TMB-8. These findings and the demonstration of an attenuation of TMB-8 inhibition of KCl responses by increasing Ca++ concentrations indicate that TMB-8 may inhibit skeletal muscle contractility by interfering with the availability of Ca++ by blocking Ca++ release from the sarcoplasmic reticulum.